Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Welichem’s Phase II eczema trial receives Canadian approval
The company will initiate its Phase IIa trial of WBI-1001 as a topical cream application in the coming months. Atopic dermatitis is normally treated topically with corticosteroids or
The company will initiate its Phase IIa trial of WBI-1001 as a topical cream application in the coming months. Atopic dermatitis is normally treated topically with corticosteroids or
The milestone has been achieved in a recently announced exclusive collaboration and license agreement with Merck & Co., through its affiliate Merck Sharp & Dohme Research. The collaboration
The trial is a randomized, double-blind safety and efficacy research study in which Excellarate is topically administered once or twice over the course of the study, with a
In addition to approving the acquisition of the Bruker BioSpin Group, stockholders also approved the name change of the company to Bruker Corporation. Tony Keller and Dirk Laukien,
According to the company, this newly planned Phase II trial is tentatively scheduled to start mid-2008 and will involve up to 500 participants at several locations in the
The company said that on February 13, 2008, the Hague District Court in the Netherlands, has decided to revoke the Dutch part of Merck Sharp & Dohme’s or
Under the terms of the agreement, the company has issued RBFSC a convertible promissory note in the principal amount of $3 million, which shall accrue interest at 8%
This study is designed to treat patients suffering from advanced thromboangitis obliterans, commonly referred to as Buerger’s disease. The condition of patients who are being enrolled in this
A minimum of 31 evaluable HD patients were required for the ATryn treatment trial. Results for 14 of these patients were already obtained from the previous study that
The study has employed a model of lung cancer in mice, which closely mimics the disease in humans. Treatment with oral PX-478 for five days resulted in significant